-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17, the official website of CDE showed that Jiangsu Zhengda Qingjiang Pharmaceutical Co.
, Ltd.
was accepted for the application of Apomilast tablets that were submitted for listing in 4 generic categories
.
According to data from Meinenet, the global sales of Apomilast tablets in 2020 will exceed US$2 billion
.
At present, no domestic generic drug company has been approved for this product.
Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Jiangxi Qingfeng Pharmaceutical and other eight companies have submitted listing applications under the new classification for review and approval
.
According to the data, Apomilast tablets (previously known as Apomilast tablets) is a small molecule inhibitor of phosphodiesterase-4 (PDE-4) developed by Sunbase.
It will be launched in the United States in 2014 and will be launched in 2021.
It was approved for listing in China in August for the treatment of psoriasis
.
Source: Mynet.
com's sales database of multinational listed companies.
In 2019, Amgen announced that it had acquired Apomilast for USD 13.
4 billion
.
In 2020, the global sales of this product will exceed 2 billion U.
S.
dollars
.
It is understood that Apomilast is the first oral drug approved for psoriasis in 20 years.
Such a heavy variety has naturally attracted the attention of domestic pharmaceutical companies
.
Source: One-key search on Mynet.
According to the data of Mynet.
com, there are currently 8 Apomilast tablets including Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Jiangxi Qingfeng Pharmaceutical, China Resources Double Crane Pharmaceutical | Nanjing Haijing Pharmaceutical, etc.
Companies submitting applications for listing under the new classification are under review and approval, involving 27 acceptance numbers, and the first imitation dispute has entered a fierce stage
.
Source: CDE official website, Minet.
com database
, Ltd.
was accepted for the application of Apomilast tablets that were submitted for listing in 4 generic categories
.
According to data from Meinenet, the global sales of Apomilast tablets in 2020 will exceed US$2 billion
.
At present, no domestic generic drug company has been approved for this product.
Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Jiangxi Qingfeng Pharmaceutical and other eight companies have submitted listing applications under the new classification for review and approval
.
According to the data, Apomilast tablets (previously known as Apomilast tablets) is a small molecule inhibitor of phosphodiesterase-4 (PDE-4) developed by Sunbase.
It will be launched in the United States in 2014 and will be launched in 2021.
It was approved for listing in China in August for the treatment of psoriasis
.
Source: Mynet.
com's sales database of multinational listed companies.
In 2019, Amgen announced that it had acquired Apomilast for USD 13.
4 billion
.
In 2020, the global sales of this product will exceed 2 billion U.
S.
dollars
.
It is understood that Apomilast is the first oral drug approved for psoriasis in 20 years.
Such a heavy variety has naturally attracted the attention of domestic pharmaceutical companies
.
Source: One-key search on Mynet.
According to the data of Mynet.
com, there are currently 8 Apomilast tablets including Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Jiangxi Qingfeng Pharmaceutical, China Resources Double Crane Pharmaceutical | Nanjing Haijing Pharmaceutical, etc.
Companies submitting applications for listing under the new classification are under review and approval, involving 27 acceptance numbers, and the first imitation dispute has entered a fierce stage
.
Source: CDE official website, Minet.
com database
